Phase 2 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with kidney cancer (renal cell carcinoma) that has spread to other parts of the body or cannot be surgically removed, confirmed by a laboratory test.
• People whose cancer got worse, or who could not tolerate, 1 to 2 previous treatments — where at least one of those treatments included an immune checkpoint inhibitor (a type of immunotherapy, possibly combined with another targeted drug); or people whose cancer came back within 12 months of receiving immunotherapy before or after surgery.
• People whose doctors (including a specialist radiation doctor) have assessed them as suitable to receive radiation therapy.
• People who are considered well enough to receive both radiation therapy and immunotherapy at the same time.
• People who have at least two areas of cancer spread (metastases) in different locations that can be measured and tracked using standard imaging criteria (called RECIST v1.1).
• People who have read, understood, and signed a consent form agreeing to take part in the study.
• People with a general health score of 0 or 1 on the ECOG scale, meaning they are either fully active or have only minor limitations in physical activity (confirm with trial site).
• People whose heart, liver, kidneys, and other major organs are working well enough to meet the study's requirements.
• People who are willing and able to attend all required appointments, tests, and procedures throughout the study.
• Women who could become pregnant must use a highly effective form of contraception from the start of the study until at least 120 days after the last dose, and must have a negative pregnancy test within 7 days before joining.
• Men who have not had a sterilisation procedure must use highly effective contraception throughout the study and for at least 120 days after the last dose.

Who may not be able to join:

• People who have had another type of cancer in the past 5 years, unless it was a cancer considered very likely to have been fully cured (such as certain thyroid cancers, early-stage cervical cancer, certain skin cancers, or breast ductal carcinoma in situ treated with surgery).
• People who received any other anti-cancer treatment — including targeted therapy, immunotherapy, local treatments, or experimental treatments — within 4 weeks before starting the trial (or within 5 half-lives of the drug, whichever applies; confirm with trial site).
• People who have had radiation therapy at any point in the past, at any location or in any form.
• People who had major surgery within 4 weeks before the trial starts, or who are still recovering from surgery.
• People with a history of severe allergic reactions to medicines, including antibody-based drugs.
• People who have a medical reason that means they cannot restart immunotherapy.
• People who have had an organ transplant or stem cell transplant from another person, particularly if they may need long-term steroid treatment as a result.
• People with unresolved side effects from previous cancer treatment that have not returned to near-normal levels (Grade 0–1 as defined by a standard medical scale), except for hair loss or certain irreversible side effects that are not expected to be made worse by the trial treatment.
• People who have cancer that has spread to the brain or the lining around the brain or spinal cord.
• People with a known history of significant liver disease.
• People with fluid build-up in the chest, abdomen, or around the heart that cannot be controlled and requires repeated draining.
• People who have taken steroid medicines or other immune-suppressing drugs within 14 days before starting the trial.
• People with any severe or uncontrolled medical condition.
• People who have, or are suspected to have, an active autoimmune disease (a condition where the immune system attacks the body), such as lupus, rheumatoid arthritis, or inflammatory bowel disease.
• People whose kidneys have failed and who need dialysis (haemodialysis or peritoneal dialysis).
• People with a known history of immune system deficiency, including HIV, other immune deficiency conditions, or a history of organ transplantation.
• People who received a live vaccine within 4 weeks before starting the trial, or who are expected to need one during the study.
• People with a history of substance misuse who are unable to stop, or people with a history of serious mental health conditions.
• Women who are pregnant or breastfeeding.
• People with other serious medical or psychiatric conditions, or significant abnormal laboratory results, that the trial doctors believe could increase the risks of taking part or make the results harder to interpret.

Important: Always verify eligibility with the trial site directly before applying.